AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study

AstraZeneca Plc's AZN Imfinzi (durvalumab) and chemoradiotherapy did not achieve the primary goal of improving survival in patients with locally advanced cervical cancer.
The Phase 3 study, dubbed "CALLA," tested progression-free survival of patients with the combination against chemoradiotherapy alone.
"While the results were not what we hoped for, insights from the trial will advance our understanding and application of immunotherapy across our broad clinical development program," Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, said in a statement.
Also Read: AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer.
The safety and tolerability in this trial were consistent between the two arms, and no new, unexpected safety findings were observed.
The data will be presented at a forthcoming medical meeting.
Price Action: AZN shares are up 0.48% at $64.63 during the premarket session on the last check Thursday.

Overview Rating:

Speculative

0100